| MRC ASTEC Trial | pelvine Lymphonodektomie beim Stadium FIGO I: kein Benefit | |
| ILIADE Trial | Piver II oder Piver II-Hystektomie beim Stadium FIGO I: kein signifikanter Unterschied | |
| GOG LAP2 | Laparotomie v. Laparoskopie | |
| GOG 33 | FIGO I ,II: Hysterektomie mit Adnexen und pelviner Lymphonodektomie, Spülzytologie | |
| EORTC 55962 | A randomized phase III trial for evaluation of usefullness of pelvic drains after radical hysterectomy and node dissection (RHND) | |
| LSK-Studie | ||
| PORTEC-1 | operiertes Endometrium - Ca FIGO IB/C | RT des pelvinen LA versus keine RT |
| PORTEC-2 | operiertes Endometrium - Ca FIGO I/IIa high/intermediate risk | 3x7Gy vaginale Brachytherapie versus 46 Gy perkutan |
| GOG 99 | OP +- Nachbestrahlung (4) | |
| RTOG 12-03, TIME-C | IMRT | A Randomized Phase III Study Of Standard Vs. IMRT Pelvic Radiation For Post-Operative Treatment Of Endometrial And Cervical Cancer (TIME-C)--RTOG CCOP Study Open Phase III |
| EORTC 55102 | OP +- Paclitaxel-Carboplatin | A phase III Trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer. offene Studie |
| PORTEC-3 | Bei Frauen mit operiertem Hochrisiko - Endometrium - Karzinom kann mit einer postoperativen Radio -Chemotherapie das Gesamtüberleben (nicht signifikant) und das rezidivfreie Überleben (p=0,022) gegenüber einer alleinigen Strahlentherapie verbessert werden. | ||
| EORTC 55991 | postoperativ RT versus Radiochemotherapie | A randomised trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high risk endometrial carcinoma. | |
| RTOG0973-GOG0238 | postoperativ RT versus Radiochemotherapie | 0973 GOG-0238/Endorsed Study: "A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus" Open II R. | |
| RTOG1073 -GOG0258 | postoperativ Carboplatin - Paclitaxel versus Radiochemotherapie | 1073 GOG-0258/Endorsed Study: "A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma" Open III | |
| RTOG 09-21 | IMRT - Cisplatin-Bevacizumab, Carboplatin-Paclitaxel | A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed By Carboplatin and Paclitaxel For Patients with Endometrial Cancer Closed Phase II | |
| RTOG 04-18 | IMRT +- Chemotherapie | 0418 A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis +/ Chemotherapy for Postoperative Patients with either Endometrial or Cervical Carcinoma Closed Phase II | |
| RTOG 97-08 | RT + Cisplatin/Taxol | 9708 A Phase II Study of Adjuvant Postoperative Irradiation Combined with Cisplatin/Taxol chemotherapy Following TAH/BSO for Patients with High-Risk Endometrial Cancer Terminated II | |
| NSABP 99-05 | RT +- Cisplatin-Paclitaxel | 9905 A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Paclitaxel Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer Terminated III | |
| AGO Uterus-4 | Docetaxel beim rezidivierten oder metastasierten Endometrium - Ca | Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer. Nicht randomisiert, daher kein Nachweis einer Wirksamkeit. |
| EORTC 55984 | AP versus TAP - Chemotherapie beim metastasierten, rezidivierten und inoperablen Endometrium - Karzinom. | A randomized trial of adriamycin (A), cisplatin(P) versus paclitaxel (T), adriamycin (A) and cisplatin (P) in patients with metastatic/relapsed or locally advanced inoperable endometrial cancer. |
| GOG 184 | Advanced Stage III-IV | Doxorubicin und Cisplatin +- Paclitaxel |
| GOG 122 | Advanced Stage III-IV (1) | randomized to whole abdominal XRT vs doxorubicin-cisplatin. o ASCO Abstract 2003 - "Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group" Randall ME et al. |
| GOG 0086-M | liposomales Doxorubicin | liposomales Doxorubicin: geringe Wirksamkeit, hohe Haematotoxizität |
| GOG-209 | GOG-209 Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125: 771-3, 2012. (Abstract) Miller D, Filiaci V, Fleming G, Mannel R, Cohn D, Matsumoto T, Tewari K, DiSilvestro P, Pearl M, Zaino R | |
| EORTC 55872 | adriamycin +- Cisplatin | Randomized phase II protocol to study adriamycin/Cisplatin in combination and adriamycin alone in patients with advanced and/or recurrent endometrial carcinoma |
| EORTC 55873 | Cyclophosphamide oder Ifosfamide | Randomized phase II protocol to study cyclophosphamide or Ifosfamide in patients with advanced and/or recurrent endometrial carcinoma |
| EORTC 55853 | Carboplatin | Phase II trial of carboplatin in advanced/recurrent endometrial carcinoma |
| EORTC 55839 | Mitoxantrone | Phase II Chemotherapy with Mitoxantrone for Recurrent and/or Disseminated Endometrial Carcinoma |
| EORTC 55112 | Aromatase IH | Efficacy of inhibitors in primary advanced or recurrent endometrial stromal sarcoma : a phase II trial. |
| Gefitinib | GOG-229C | GOG-229C A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 129(3): 486-94, 2013. Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Schilder RJ, Singh M, Maihle NJ |
| Lapatinib | GOG-229D | GOG-229D Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 127(2): 345-50, 2012. Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG |
| Bevacizumab | GOG-229E | GOG-229E Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 29(16): 2259-65, 2011. Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK |
| Aflibercept | GOG-229F | GOG-229F A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 127(3): 538-43, 2012. Click Here Click Here Coleman RL, Sill MW, Lankes HA, Nickles Fader A, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh K, Sood AK |
| Bevacizumab und Temsirolimus | GOG-229G | GOG-229G Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 129(1): 22-7, 2013. Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn D, Harrison CR, Moore K, Aghajanian C |
| MEK-1/2 inhibitor | GOG-229H | GOG-229H A phase II evaluation of AZD6244, a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol : , 2012. (Abstract) (In Press) Coleman RL, Sill MW, Thaker P, Bender DP,De Geest K, Street D, McGuire W, Rotmensch J |
| Brivanib | GOG-229I | GOG-229I A phase II trial of brivanib in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Int J Gynecol Cancer 22(8); s3: E115, 2012. (Abstract) Powell MA, Sill MW, Goodfellow PJ, Jeske YW, Leslie KK, Lankes HA, Pollock PM |
| Temsirolimus | GOG-248 (5) | Hormonal therapy plus temsirolimus for endometrial carcinoma |
| Thalidomid | GOG-229B | GOG-229B A phase II trial of thalidomide in patients with persistent or recurrent endometrial cancer with translational research: a Gynecologic Oncology Group study. Gynecol Oncol 105(2): 508-16, 2007. Here McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD |
| Pembrolizumab | KEYNOTE-158 | Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study (7) |
| KEYNOTE-775 | Fortgeschrittenes Endometriumkarzinom: Multikinase-IH (Lenvatinib) plus Checkpoint-Hemmer (Pembrolizumab) ist effektiver als Doxorubicin- oder platinbasierte Chemotherapie |
Teil von
Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
J Clin Oncol 24 (2006): 36-44
2. Creutzberg CL, van Putten WLJ, Koper PCM, Lybeert MLM, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van den Bergh ACM, van de Steen-Banasik E, Beerman H, van Lent M, for the PORTEC Study Group.
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial.
The Lancet 2000; 355: 1404-1411
3. Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KA, Lutgens LC, van Lent M, Creutzberg CL; PORTEC Study Group.
Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review.
Int J Radiat Oncol Biol Phys 2005; 63: 834-838
4.) Keys HM, Roberts JA, Brunetto VL, et al:
A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study.
Gynecol Oncol 92(2004):744-751
5.) Fleming GF, et al.:
Hormonal therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248.
J Clin Oncol 29(2011): 15s, ASCO #5014: 335s (Abstract)
6.) Matei D, et al.:
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
N Engl J Med 2019;380:2317-26.
DOI: 10.1056/NEJMoa1813181
7.) O’Malley D M, et al.:
Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
J Clin Oncol 2022;40:752-761